Bide Pharmatech Co

Bide Pharmatech Co EBITDA per Share

The EBITDA per Share of Bide Pharmatech Co (688073.SS) as of Oct 22, 2026 is 2.66 CNY. In the previous year, EBITDA per Share was 1.98 CNY — a change of 34.16% (higher).

EBITDA per Share

2.66CNY

YoY

34.16%

Last updated:

EBITDA per Share of Bide Pharmatech Co is 2025 2.66 CNY. EBITDA per Share of Bide Pharmatech Co was 2024 1.98 CNY. It decreases by 34.16% higher compared to the previous year.

The Bide Pharmatech Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
0.17 CNY
Jan 1, 2020
1.09 CNY
Jan 1, 2021
1.48 CNY
Jan 1, 2022
1.98 CNY
Jan 1, 2023
1.62 CNY
Jan 1, 2024
1.98 CNY
Jan 1, 2025
2.66 CNY
The Bide Pharmatech Co EBITDA per Share history
YEAREBITDA per ShareYoY
2.66CNY+34.16%
1.98CNY+22.05%
1.62CNY-18.15%
1.98CNY+33.92%
1.48CNY+36.14%
1.09CNY+538.68%
0.17CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

EBITDA per Share of Bide Pharmatech Co is 2.66 CNY in 2025.

EBITDA per Share of Bide Pharmatech Co changed from 1.98 CNY to 2.66 CNY, representing a 34.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co